Twist Bioscience Launches Antibody Screening Service
The new service utilizes a cell-free production system to provide purified antibodies for research in as little as five days.
Updated on Oct. 29, 2026 in Biotech
Live Poll
Do you trust that faster, AI-driven drug development will lead to better health outcomes?
Twist Bioscience has introduced an antibody screening service that allows researchers to quickly produce and evaluate large numbers of candidates. By integrating LenioBio's ALiCE eukaryotic expression system, the company aims to support the fast-paced demands of AI-driven drug discovery.
Why it matters
As AI-based drug discovery accelerates the identification of potential treatments, researchers require faster ways to validate large candidate pools. This service streamlines the transition from digital discovery to physical testing by enabling rapid production and binding characterization.
The platform supports full-length IgG, single-chain variable fragment-Fc, and VHH-Fc antibody formats. Purified antibodies are delivered in quantities of 5 to 20 micrograms using a high-throughput cell-free workflow.
The players
Twist Bioscience
A biotechnology company that specializes in manufacturing synthetic DNA and providing tools for various research and pharmaceutical applications.
LenioBio
A biotechnology firm that developed the ALiCE system, a cell-free eukaryotic protein expression technology used for large-scale protein production.
The details
The workflow employs a cell-free production process to deliver purified full-length immunoglobulin G antibodies along with binding characterization via surface plasmon resonance. This method provides a scalable solution for evaluating antibody candidates generated through computational models.
Timeline
Twist Bioscience launched the service on October 29, 2026.
The Tech Race
The integration of the ALiCE eukaryotic expression system marks a significant shift toward cell-free production models that replace labor-intensive, cell-based protein manufacturing. This positions Twist Bioscience to better compete in the rapidly expanding market for high-speed biological validation.
Researchers can now shorten their development timelines, potentially accelerating the early stages of preclinical drug discovery. This rapid turnaround allows labs to test more antibody variations with less material waste, improving the efficiency of the research workflow.
The takeaway
The shift toward cell-free production underscores a broader push for efficiency in biological research as digital tools generate candidate data faster than traditional methods can verify. Researchers looking to adopt these workflows should ensure their internal screening assays are compatible with the specific antibody formats offered.
Further reading
Learn more about advancements in the Biotech sector on our platform.
Source note: This article includes information reported by Pharmafocusasia.
Live Poll
Do you trust that faster, AI-driven drug development will lead to better health outcomes?
